Paradice Investment Management LLC Trims Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Paradice Investment Management LLC decreased its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 28.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,081,886 shares of the medical device company's stock after selling 438,179 shares during the quarter. Tandem Diabetes Care makes up approximately 4.0% of Paradice Investment Management LLC's portfolio, making the stock its 10th biggest position. Paradice Investment Management LLC owned 1.66% of Tandem Diabetes Care worth $32,002,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. RiverPark Advisors LLC acquired a new position in shares of Tandem Diabetes Care during the fourth quarter worth $27,000. Signaturefd LLC grew its position in shares of Tandem Diabetes Care by 871.8% in the 4th quarter. Signaturefd LLC now owns 1,691 shares of the medical device company's stock valued at $50,000 after buying an additional 1,517 shares during the last quarter. GAMMA Investing LLC bought a new stake in shares of Tandem Diabetes Care in the 4th quarter valued at about $73,000. PNC Financial Services Group Inc. increased its stake in shares of Tandem Diabetes Care by 51.7% in the third quarter. PNC Financial Services Group Inc. now owns 3,226 shares of the medical device company's stock valued at $67,000 after buying an additional 1,099 shares during the period. Finally, Creative Financial Designs Inc. ADV bought a new position in shares of Tandem Diabetes Care during the fourth quarter worth about $104,000.

Tandem Diabetes Care Stock Up 0.8 %

NASDAQ:TNDM traded up $0.37 during trading hours on Friday, hitting $47.30. 1,123,194 shares of the company traded hands, compared to its average volume of 1,700,611. Tandem Diabetes Care, Inc. has a one year low of $13.82 and a one year high of $47.88. The company has a quick ratio of 3.01, a current ratio of 3.81 and a debt-to-equity ratio of 1.43. The company has a market cap of $3.06 billion, a PE ratio of -21.80 and a beta of 1.10. The firm's 50-day simple moving average is $35.59 and its 200-day simple moving average is $27.90.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last issued its quarterly earnings results on Wednesday, February 21st. The medical device company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.04). The business had revenue of $196.80 million for the quarter, compared to the consensus estimate of $204.86 million. Tandem Diabetes Care had a negative return on equity of 34.38% and a negative net margin of 18.37%. Equities analysts predict that Tandem Diabetes Care, Inc. will post -1.7 earnings per share for the current year.

Analyst Upgrades and Downgrades

TNDM has been the subject of a number of recent analyst reports. Stifel Nicolaus increased their target price on shares of Tandem Diabetes Care from $37.00 to $40.00 and gave the company a "buy" rating in a research report on Tuesday, April 23rd. Robert W. Baird increased their price objective on shares of Tandem Diabetes Care from $28.00 to $36.00 and gave the stock a "neutral" rating in a research report on Friday, May 3rd. Barclays boosted their target price on shares of Tandem Diabetes Care from $39.00 to $55.00 and gave the company an "overweight" rating in a report on Monday, May 6th. StockNews.com upgraded Tandem Diabetes Care from a "sell" rating to a "hold" rating in a report on Friday, April 19th. Finally, Citigroup boosted their price objective on Tandem Diabetes Care from $31.00 to $38.00 and gave the company a "neutral" rating in a research note on Wednesday, April 3rd. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $43.80.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.